Avita share price dives 16% on net loss

The medical technology company's shares are falling following today's financial results

| More on:
A sad looking scientist sitting and upset about a share price fall.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The Avita Medical share price is descending today 
  • The company's net loss jumped by 47% in the first half of the year 
  • Operating expenses increased in the first half of the year

The AVITA Medical Inc (ASX: AVH) share price is falling on the back of the company's financial results.

The medical technology company's share price is currently $1.895, a 16.5% fall. For perspective, the S&P/ASX 200 Index (ASX: XJO) is down 0.6% today.

Let's take a look at what Avita reported to the market today.

Avita reports a higher net loss

Avita reported both quarterly and half-year results for the 2022 calendar year.

In the first six months of 2022, Avita reported:

  • Net loss jumped by 47% to $15.7 million, compared to $10.7 million loss in prior corresponding period (pcp)
  • Gross profit margin increased by 2% to 80% compared to pcp
  • Adjusted earnings before interest, taxes, depreciation, and amortisation (EBITDA) loss jumped 46% to $11.1 million on pcp
  • Commercial revenue excluding Biomedical Advance Research Development Authority (BARDA) revenue jumped 39% to $4.4 million
  • Total revenue including BARDA revenue of $15.9 million, down from $19.1 million in pcp

Second-quarter results included:

  • Net loss up 33% to $6.3 million
  • Adjusted EBITDA loss leapt 51% to $4.7 million
  • Gross profit margin jumped by 3% to 83% on pcp
  • Commercial revenue excluding BARDA revenue leapt 23% to $8.2 million
  • Total revenue including BARDA revenue of $8.3 million, down from $10.3 million on pcp

What else did the company report?

Operating expenses surged 12% on the pcp to $29.9 million in the first six months of the year. This was largely due to greater compensation costs and professional fees.

Lower clinical trial expenses partly offset these higher costs. Research and development costs were also lower compared to the pcp.

Avita highlighted the commercial revenue growth was due to more customers and order sizes increasing.

Avita has $91.1 million of cash, cash equivalents and marketable securities available as of 30 June and no debt.

The company is providing a calendar year 2022 revenue guidance of $30 million, excluding BARDA revenues. BARDA revenues are expected to be $0.3 million in 2022 compared to $7.9 million in 2021.

What did management say?

Commenting on the results, chief executive officer Dr Mike Perry said:

Our commercial team continued to drive further RECELL utilisation and penetration within burn centres, and our clinical team advanced our soft tissue reconstruction and vitiligo trial.

We look forward to topline data from our vitiligo clinical trial in the second half of this year.

Topline results from pivotal trial

Avita also reported topline results from a trial looking into the company's RECELL system to heal soft tissue reconstruction with reduced donor skin.

The results showed "statistically superior donor sparing" and "comparable healing rates" in the treatment of soft tissue injuries.

Further commenting on the trial, Dr Perry said:

The RECELL system has been used to effectively treat serious burn injuries and we anticipate that the RECELL system will be well-positioned to treat patients with soft-tissue injuries, pending FDA review and approval.

Avita share price snapshot

The Avita share price has dived 45% in the year to date. However, it has gained 14% in the past month.

For perspective, the benchmark ASX 200 index has lost more than 5% in the year to date but climbed nearly 7% in a month.

Motley Fool contributor Monica O'Shea has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Avita Medical Limited. The Motley Fool Australia has recommended Avita Medical Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Earnings Results

Miner looking at a tablet.
Earnings Results

Rio Tinto share price on watch following FY 2023 earnings miss

Rio Tinto's iron ore operations were on form in 2023. It's a shame the rest of the business wasn't.

Read more »

Man with rocket wings which have flames coming out of them.
Earnings Results

4 All Ords ASX dividend shares going gangbusters on results

All Ords investors are sending these ASX dividend shares soaring on the back of their earnings results.

Read more »

Man waiting for his flight and looking at his phone.
Earnings Results

Corporate Travel share price plunges 18% despite tripling net profits

An explosion in earnings is taking a backseat to changes in Corporate Travel Management's full-year forecasts.

Read more »

happy woman throws arms in the air
Bank Shares

NAB shares hit 52-week high on first-quarter earnings beat

NAB appears on track to at least deliver on first-half expectations.

Read more »

A man wearing a shirt, tie and hard hat sits in an office and marks dates in his diary.
Earnings Results

Santos share price slips on 42% profit drop in FY23 result

Profits come back down to Earth in FY23.

Read more »

a man sits on a ridge high above a large city full of high rise buildings as though he is thinking, contemplating the vista below.
REITs

Here are 4 ASX 200 REITs results catching the eye on Wednesday

A mixed set of results have been announced by these property companies.

Read more »

Three analysts look at tech options on a wall screen
Earnings Results

WiseTech share price leaps 8% today as revenues surge

ASX 200 investors are bidding up the WiseTech share price today.

Read more »

Two parents and two children happily eat pizza in their kitchen as a top broker predicts a 46% upside for the Domino's share price
Earnings Results

Domino's share price charges higher on improving outlook

Here's how this struggling pizza chain operator performed during the first half.

Read more »